JP2013531240A5 - - Google Patents

Info

Publication number

JP2013531240A5

JP2013531240A5 JP2013516566A JP2013516566A JP2013531240A5 JP 2013531240 A5 JP2013531240 A5 JP 2013531240A5 JP 2013516566 A JP2013516566 A JP 2013516566A JP 2013516566 A JP2013516566 A JP 2013516566A JP 2013531240 A5 JP2013531240 A5 JP 2013531240A5

Authority

JP

Japan

Prior art keywords

hours

subject

fluid sample

time

motif chemokine

Prior art date

2011-06-23

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Pending

Links

• Espacenet
• Global Dossier
• Discuss

• DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 claims 38
• 238000000034 method Methods 0.000 claims 26
• 102000019034 Chemokines Human genes 0.000 claims 22
• 108010012236 Chemokines Proteins 0.000 claims 22
• 210000001124 body fluid Anatomy 0.000 claims 20
• 229940109239 creatinine Drugs 0.000 claims 19
• 210000002966 serum Anatomy 0.000 claims 19
• 238000003556 assay Methods 0.000 claims 15
• 210000002700 urine Anatomy 0.000 claims 13
• 208000009304 Acute Kidney Injury Diseases 0.000 claims 9
• 208000033626 Renal failure acute Diseases 0.000 claims 9
• 201000011040 acute kidney failure Diseases 0.000 claims 9
• 208000012998 acute renal failure Diseases 0.000 claims 9
• 239000012530 fluid Substances 0.000 claims 7
• 210000003734 kidney Anatomy 0.000 claims 7
• NMWKYTGJWUAZPZ-WWHBDHEGSA-N (4S)-4-[[(4R,7S,10S,16S,19S,25S,28S,31R)-31-[[(2S)-2-[[(1R,6R,9S,12S,18S,21S,24S,27S,30S,33S,36S,39S,42R,47R,53S,56S,59S,62S,65S,68S,71S,76S,79S,85S)-47-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-methylbutanoyl]amino]-3-methylbutanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-4-yl)propanoyl]amino]-3-phenylpropanoyl]amino]-4-oxobutanoyl]amino]-3-carboxypropanoyl]amino]-18-(4-aminobutyl)-27,68-bis(3-amino-3-oxopropyl)-36,71,76-tribenzyl-39-(3-carbamimidamidopropyl)-24-(2-carboxyethyl)-21,56-bis(carboxymethyl)-65,85-bis[(1R)-1-hydroxyethyl]-59-(hydroxymethyl)-62,79-bis(1H-imidazol-4-ylmethyl)-9-methyl-33-(2-methylpropyl)-8,11,17,20,23,26,29,32,35,38,41,48,54,57,60,63,66,69,72,74,77,80,83,86-tetracosaoxo-30-propan-2-yl-3,4,44,45-tetrathia-7,10,16,19,22,25,28,31,34,37,40,49,55,58,61,64,67,70,73,75,78,81,84,87-tetracosazatetracyclo[40.31.14.012,16.049,53]heptaoctacontane-6-carbonyl]amino]-3-methylbutanoyl]amino]-7-(3-carbamimidamidopropyl)-25-(hydroxymethyl)-19-[(4-hydroxyphenyl)methyl]-28-(1H-imidazol-4-ylmethyl)-10-methyl-6,9,12,15,18,21,24,27,30-nonaoxo-16-propan-2-yl-1,2-dithia-5,8,11,14,17,20,23,26,29-nonazacyclodotriacontane-4-carbonyl]amino]-5-[[(2S)-1-[[(2S)-1-[[(2S)-3-carboxy-1-[[(2S)-1-[[(2S)-1-[[(1S)-1-carboxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-5-oxopentanoic acid Chemical compound CC(C)C[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@@H](NC(=O)[C@@H]2CSSC[C@@H]3NC(=O)[C@H](Cc4ccccc4)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](Cc4c[nH]cn4)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H]4CCCN4C(=O)[C@H](CSSC[C@H](NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](Cc4c[nH]cn4)NC(=O)[C@H](Cc4ccccc4)NC3=O)[C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc3ccccc3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N3CCC[C@H]3C(=O)N[C@@H](C)C(=O)N2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2c[nH]cn2)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)C(C)C)C(=O)N[C@@H](Cc2c[nH]cn2)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1)C(=O)N[C@@H](C)C(O)=O NMWKYTGJWUAZPZ-WWHBDHEGSA-N 0.000 claims 6
• 102000003908 Cathepsin D Human genes 0.000 claims 6
• 108090000258 Cathepsin D Proteins 0.000 claims 6
• 108090000177 Interleukin-11 Proteins 0.000 claims 6
• 102000003815 Interleukin-11 Human genes 0.000 claims 6
• 102000007298 Mucin-1 Human genes 0.000 claims 6
• 108010008707 Mucin-1 Proteins 0.000 claims 6
• 206010028980 Neoplasm Diseases 0.000 claims 6
• 102000056189 Neutrophil collagenases Human genes 0.000 claims 6
• 108030001564 Neutrophil collagenases Proteins 0.000 claims 6
• 102000006747 Transforming Growth Factor alpha Human genes 0.000 claims 6
• 101800004564 Transforming growth factor alpha Proteins 0.000 claims 6
• 239000010839 body fluid Substances 0.000 claims 6
• 201000011510 cancer Diseases 0.000 claims 6
• 229940074383 interleukin-11 Drugs 0.000 claims 6
• 102000004374 Insulin-like growth factor binding protein 3 Human genes 0.000 claims 5
• 108090000965 Insulin-like growth factor binding protein 3 Proteins 0.000 claims 5
• 102000007351 Interleukin-2 Receptor alpha Subunit Human genes 0.000 claims 4
• 108010032774 Interleukin-2 Receptor alpha Subunit Proteins 0.000 claims 4
• 239000003153 chemical reaction reagent Substances 0.000 claims 4
• LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims 3
• 206010061481 Renal injury Diseases 0.000 claims 3
• 239000000090 biomarker Substances 0.000 claims 3
• 102100025277 C-X-C motif chemokine 13 Human genes 0.000 claims 2
• 101710098309 C-X-C motif chemokine 13 Proteins 0.000 claims 2
• 230000027455 binding Effects 0.000 claims 2
• 230000003907 kidney function Effects 0.000 claims 2
• 102000005962 receptors Human genes 0.000 claims 2
• 108020003175 receptors Proteins 0.000 claims 2
• 238000012959 renal replacement therapy Methods 0.000 claims 2
• 238000002054 transplantation Methods 0.000 claims 2
• 206010007559 Cardiac failure congestive Diseases 0.000 claims 1
• PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims 1
• 108010036949 Cyclosporine Proteins 0.000 claims 1
• 206010016654 Fibrosis Diseases 0.000 claims 1
• 206010019280 Heart failures Diseases 0.000 claims 1
• 102000001554 Hemoglobins Human genes 0.000 claims 1
• 108010054147 Hemoglobins Proteins 0.000 claims 1
• 206010020772 Hypertension Diseases 0.000 claims 1
• FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims 1
• 102100030856 Myoglobin Human genes 0.000 claims 1
• 108010062374 Myoglobin Proteins 0.000 claims 1
• 208000001647 Renal Insufficiency Diseases 0.000 claims 1
• 206010040047 Sepsis Diseases 0.000 claims 1
• ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 claims 1
• QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 claims 1
• 208000027418 Wounds and injury Diseases 0.000 claims 1
• 229940126575 aminoglycoside Drugs 0.000 claims 1
• 238000007675 cardiac surgery Methods 0.000 claims 1
• 229960001265 ciclosporin Drugs 0.000 claims 1
• 230000007882 cirrhosis Effects 0.000 claims 1
• 208000019425 cirrhosis of liver Diseases 0.000 claims 1
• 238000012875 competitive assay Methods 0.000 claims 1
• 239000002872 contrast media Substances 0.000 claims 1
• 208000029078 coronary artery disease Diseases 0.000 claims 1
• 210000004351 coronary vessel Anatomy 0.000 claims 1
• 229930182912 cyclosporin Natural products 0.000 claims 1
• 230000006378 damage Effects 0.000 claims 1
• 206010012601 diabetes mellitus Diseases 0.000 claims 1
• 238000003745 diagnosis Methods 0.000 claims 1
• 208000002296 eclampsia Diseases 0.000 claims 1
• 238000011156 evaluation Methods 0.000 claims 1
• 230000006870 function Effects 0.000 claims 1
• 230000024924 glomerular filtration Effects 0.000 claims 1
• 102000028718 growth factor binding proteins Human genes 0.000 claims 1
• 108091009353 growth factor binding proteins Proteins 0.000 claims 1
• 229910001385 heavy metal Inorganic materials 0.000 claims 1
• HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 claims 1
• 229960001101 ifosfamide Drugs 0.000 claims 1
• 208000014674 injury Diseases 0.000 claims 1
• 230000002608 insulinlike Effects 0.000 claims 1
• 201000006370 kidney failure Diseases 0.000 claims 1
• 229960000485 methotrexate Drugs 0.000 claims 1
• 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims 1
• 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims 1
• 201000011461 pre-eclampsia Diseases 0.000 claims 1
• 238000004393 prognosis Methods 0.000 claims 1
• 201000001474 proteinuria Diseases 0.000 claims 1
• 238000012493 sandwich binding assay Methods 0.000 claims 1
• ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 claims 1
• 229960001052 streptozocin Drugs 0.000 claims 1
• 229960001967 tacrolimus Drugs 0.000 claims 1
• QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 claims 1
• 230000002485 urinary effect Effects 0.000 claims 1
• 230000036325 urinary excretion Effects 0.000 claims 1
• 238000007631 vascular surgery Methods 0.000 claims 1